Inventor · disambiguated record
Baiyong Li
Also filed as: LI BAIYONG
19 granted patents·31 pending applications·34 citations·filing 2001–2024
91Inventor score
Files withAKESO BIOPHARMA INC32AKESO PHARMACEUTICALS INC5CTTQ AKESO SHANGHAI BIOMED TECH CO LTD3AD PHARMACEUTICAL CO INC2SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD2
Top patents by PatentIndex Score
50 records- 0194US12195527B2Anti-PD-1/VEGFA bifunctional antibody, pharmaceutical composition thereofAKESO BIOPHARMA INC·Filed 2023·Granted Jan 14, 2025·2 cites·24 claims
- 0291US11578128B2Anti-CTLA4 and anti-PD-1 bifunctional antibody, pharmaceutical composition thereof and use thereofAKESO PHARMACEUTICALS INC·Filed 2017·Granted Feb 14, 2023·7 cites·29 claims
- 0391US10449251B2Anti-CTLA4 monoclonal antibody or its antigen binding fragments, pharmaceutical compositions and usesAKESO BIOPHARMA INC·Filed 2015·Granted Oct 22, 2019·6 cites·20 claims
- 0483US12076398B2Anti-PD1 monoclonal antibody, pharmaceutical composition thereof and use thereofCTTQ AKESO SHANGHAI BIOMED TECH CO LTD·Filed 2017·Granted Sep 3, 2024·3 cites·6 claims
- 0581US2025223346A1Monoclonal antibody against nerve growth factor, and encoding gene and use thereofAKESO BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 0681US2025197487A1Anti-pd-1/vegfa bifunctional antibody, pharmaceutical composition thereof and use thereofAKESO BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 0780US11136413B2PDL-1 antibody, pharmaceutical composition thereof, and uses thereofSICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD·Filed 2019·Granted Oct 5, 2021·1 cites·40 claims
- 0879US10670604B2PCSK9 antibody, and pharmaceutical composition and use thereofAD PHARMACEUTICAL CO INC·Filed 2016·Granted Jun 2, 2020·2 cites·12 claims
- 0978US11402383B2Nucleic acid encoding PCSK9 antibodyAD PHARMACEUTICAL CO INC·Filed 2020·Granted Aug 2, 2022·1 cites·19 claims
- 1078US10465014B2PDL-1 antibody, pharmaceutical composition thereof, and uses thereofSICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD·Filed 2017·Granted Nov 5, 2019·1 cites·64 claims
- 1177US12447208B2Anti-CTLA4 monoclonal antibody or its antigen binding fragments, pharmaceutical compositions and usesAKESO BIOPHARMA INC·Filed 2022·Granted Oct 21, 2025·0 cites·14 claims
- 1277US11479608B2Anti-CTLA4 antibodiesAKESO BIOPHARMA INC·Filed 2017·Granted Oct 25, 2022·1 cites·24 claims
- 1375US2024025983A1Monoclonal antibody against nerve growth factor, and encoding gene and use thereofAKESO BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 1475US2025041409A1Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereofCTTQ AKESO SHANGHAI BIOMED TECH CO LTD·Filed 2024·Application pending·0 cites
- 1573US12479919B2Anti-CTLA4 and anti-PD-1 bifunctional antibody, pharmaceutical composition thereof and use thereofAKESO PHARMACEUTICALS INC·Filed 2022·Granted Nov 25, 2025·0 cites·22 claims
- 1673US12390458B2Therapeutic combination of quinoline derivative and antibodyCHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD·Filed 2019·Granted Aug 19, 2025·1 cites·14 claims
- 1772US2025368735A1Bispecific antibody containing anti-cldn18.2 antibody, and pharmaceutical composition and use thereofAKESO BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 1872US2025376517A1Anti-cldn18.2 antibody, and pharmaceutical composition and use thereofAKESO BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 1970US11291720B2Anti-CTLA4 monoclonal antibody or its antigen binding fragments, pharmaceutical compositions and usesAKESO BIOPHARMA INC·Filed 2019·Granted Apr 5, 2022·0 cites·35 claims
- 2069US2024392040A1Anti-lag3 bispecific antibody, pharmaceutical composition and useAKESO HUIKE SHANGHAI CO LTD·Filed 2022·Application pending·0 cites
- 2169US2025042995A1Anti-lag3 antibody, pharmaceutical composition and useAKESO BIOPHARMA INC·Filed 2022·Application pending·0 cites
- 2268US2021340239A1Anti-pd-1/vegfa bifunctional antibody, pharmaceutical composition thereof and use thereofAKESO BIOPHARMA INC·Filed 2019·Application pending·0 cites
- 2367US6878522B2Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2Filed 2001·Granted Apr 12, 2005·9 cites·11 claims
- 2464US12286473B2Anti-IL-1β antibody and pharmaceutical composition thereof and use of sameAKESO BIOPHARMA INC·Filed 2019·Granted Apr 29, 2025·0 cites·21 claims
- 2564US2025304703A1Anti-human il-4ra antibody and application thereofAKESO BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 2663US11680095B2Monoclonal antibody against nerve growth factor, and encoding gene and use thereofAKESO BIOPHARMA INC·Filed 2019·Granted Jun 20, 2023·0 cites·21 claims
- 2763US2024117051A1Therapeutic combination and use thereofAKESO BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 2863US2025129163A1Pharmaceutical composition and use thereofAKESO BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 2963US2025034253A1Pharmaceutical composition comprising anti-tigit antibody and anti-pd-1/anti-vegfa bispecific antibody, and use thereofAKESO BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 3062US2025188164A1Pharmaceutical composition comprising anti-ctla4-anti-pd-1 bispecific antibody and chiauranibAKESO PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3161US2025319169A2FUSION PROTEIN CONTAINING ANTI-TIGIT ANTIBODY AND TGF-ßR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOFAKESO BIOPHARMA INC·Filed 2022·Application pending·0 cites
- 3260US2024352153A1Pharmaceutical composition and useAKESO BIOPHARMA INC·Filed 2022·Application pending·0 cites
- 3358US2025114450A1Pharmaceutical combination containing anti-pd-1-anti-vegfa bispecific antibody, and use thereofAKESO BIOPHARMA INC·Filed 2022·Application pending·0 cites
- 3458US2024043531A1Anti-cd47 monoclonal antibody and use thereofAKESO BIOPHARMA INC·Filed 2022·Application pending·0 cites
- 3557US2024002504A1Anti-tigit antibody, and pharmaceutical composition and use thereofAKESO BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 3657US2024018254A1Anti-cd73 antibody and use thereofAKESO BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 3756US2024218074A1Anti-cd73 antibody and use thereofAKESO BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 3854US2024199741A1Use of antibody in anti-tumor treatmentAKESO PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3954US2023159655A1Anti-cd73 antibody and use thereofAKESO BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 4054US2023151111A1Anti-cd73-anti-pd-1 bispecific antibody and use thereofAKESO BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 4153US2023312750A1Anti-pcsk9 antibody and use thereofAD PHARMACEUTICALS CO LTD·Filed 2020·Application pending·0 cites
- 4252US2023027029A1Anti-pd-1-anti-vegfa bispecific antibody, pharmaceutical composition and use thereofAKESO BIOPHARMA INC·Filed 2020·Application pending·0 cites
- 4350US10858433B2Monoclonal antibody against PD-1 and application thereofTAIZHOU HANZHONG BIOPHARMACEUTICS INC·Filed 2019·Granted Dec 8, 2020·0 cites·7 claims
- 4450US2022324971A1Anti-cd47 monoclonal antibody and use thereofAKESO BIOPHARMA INC·Filed 2020·Application pending·0 cites
- 4550US2023295312A1Antibody against human il-4ra and use thereofAKESO BIOPHARMA INC·Filed 2019·Application pending·0 cites
- 4649US2022275089A1Anti-ctla4-anti-pd-1 bispecific antibody and uses thereofAKESO PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 4747US11976115B2Antibody binding to human IL-1β, preparation method therefor and use thereofZEDA BIOPHARMACEUTICALS INC·Filed 2019·Granted May 7, 2024·0 cites·14 claims
- 4847US11104734B2Anti-PD-1 monoclonal antibodyAKESO BIOPHARMA INC·Filed 2018·Granted Aug 31, 2021·0 cites·6 claims
- 4947US2021122815A1Anti-interleukin-17a antibody, pharmaceutical composition thereof and use thereofAKESO BIOPHARMA INC·Filed 2019·Application pending·0 cites
- 5046US2022267444A1Anti-pd-1 antibody and medical use thereofCTTQ AKESO SHANGHAI BIOMED TECH CO LTD·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Baiyong Li files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →